申请人:Incyte Corporation
公开号:US20190134040A1
公开(公告)日:2019-05-09
The present invention provides heterocyclylamine derivatives of Formula I:
wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.